Cargando…

Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab

Budigalimab, a novel anti–PD-1 monoclonal antibody, demonstrated efficacy and biomarker pharmacodynamics in patients with head and neck squamous cell carcinoma (HNSCC) or non–small cell lung cancer (NSCLC) consistent with those reported by other PD-1 inhibitors. Herein are presented additional outco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lambert, Stacie L., Zhang, Chun, Guo, Claire, Turan, Tolga, Masica, David L., Englert, Stefan, Fang, Yuni, Sheridan, James, McLaughlin, Robert Tyler, Tribouley, Catherine, Vosganian, Greg, Afar, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Clinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906246/ https://www.ncbi.nlm.nih.gov/pubmed/35034046 http://dx.doi.org/10.1097/CJI.0000000000000408

Ejemplares similares

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)
por: Powderly, John, et al.
Publicado: (2020)

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
por: Italiano, Antoine, et al.
Publicado: (2021)

Fast, accurate, and racially unbiased pan-cancer tumor-only variant calling with tabular machine learning
por: McLaughlin, R. Tyler, et al.
Publicado: (2023)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment
por: Laubach, Kyra, et al.
Publicado: (2023)

Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults
por: Lingblom, Christine M. D., et al.
Publicado: (2018)

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
por: Zeitlinger, Markus, et al.
Publicado: (2023)

1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI)
por: Avery, Lindsay, et al.
Publicado: (2018)

Altered development of hippocampus-dependent associative learning following early-life adversity
por: Lambert, Hilary K., et al.
Publicado: (2019)

Introduction to the special issue on childhood adversity and neurodevelopment
por: Sheridan, Margaret A., et al.
Publicado: (2022)

Pharmacodynamic effects of daclizumab in the intrathecal compartment
por: Komori, Mika, et al.
Publicado: (2017)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin and PK/PD Modeling against Escherichia coli in Pigs
por: Lei, Zhixin, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus
por: Rox, Katharina, et al.
Publicado: (2022)

Chance or Choice
por: McLaughlin, Greg, et al.
Publicado: (2013)

ENOVALE
por: McLaughlin, Greg, et al.
Publicado: (2017)

Distinct aspects of the early environment contribute to associative memory, cued attention, and memory-guided attention: Implications for academic achievement
por: Rosen, Maya L., et al.
Publicado: (2019)

1103. Minocycline (MIN) Pharmacodynamics (PD) against Stenotrophomonas maltophilia (STM) in a Neutropenic Murine Thigh Infection Model
por: Fratoni, Andrew J, et al.
Publicado: (2021)

iBRIDGE: A Data Integration Method to Identify Inflamed Tumors from Single-cell RNA-Seq Data and Differentiate Cell Type–Specific Markers of Immune-Cell Infiltration
por: Turan, Tolga, et al.
Publicado: (2023)

1535. Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of Cefepime (CPM) in Obese and Non-Obese Patients
por: Morrisette, Taylor, et al.
Publicado: (2019)

Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin Against Streptococcus suis in Piglets
por: Wang, Rui-Ling, et al.
Publicado: (2022)

Towards Increasing the Clinical Relevance of In Silico Methods to Predict Pathogenic Missense Variants
por: Masica, David L., et al.
Publicado: (2016)

1560. Pharmacokinetics–Pharmacodynamics (PK-PD) of Gepotidacin (GEP) Against Escherichia coli in Murine Pyelonephritis and Thigh Infection Models
por: Barth, Aline, et al.
Publicado: (2019)

PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS
por: Allard, Martine, et al.
Publicado: (2023)

Working memory filtering continues to develop into late adolescence
por: Peverill, Matthew, et al.
Publicado: (2016)

Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of ceftiofur after a single intravenous, subcutaneous and subcutaneous-LA administration in lactating goats
por: Fernández-Varón, Emilio, et al.
Publicado: (2016)

Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer
por: Schalper, Kurt Alex, et al.
Publicado: (2015)

Lack of Clinically Relevant Effect of Bictegravir (BIC, B) on Metformin (MET) Pharmacokinetics (PK) and Pharmacodynamics (PD)
por: Custodio, Joseph, et al.
Publicado: (2017)

Chinese ICU physicians’ knowledge of antibiotic pharmacokinetics/pharmacodynamics (PK/PD): a cross-sectional survey
por: Mao, Wenchao, et al.
Publicado: (2022)

Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers
por: Shao, Yilin, et al.
Publicado: (2021)

Innovative Data Science to Transform Health Care: All the Pieces Matter
por: Masica, Andrew L., et al.
Publicado: (2019)

PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results
por: Noyce, Alastair J, et al.
Publicado: (2014)

Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone
por: Lal, Ritu, et al.
Publicado: (2015)

Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib
por: Yeo, Astrid, et al.
Publicado: (2017)

Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action
por: Kostov, Rumen V., et al.
Publicado: (2015)

Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model
por: Zhao, Yongda, et al.
Publicado: (2018)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ncnpm94h23cgv53rbc3e6v0q0o